Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | HCK | P08631 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2537794 | 0.87 | ACACB (0.34) | ACACBBRD4 | |
| SCHEMBL1880922 | 0.80 | BRD4 (0.37) | BRD4 | |
| SCHEMBL1885979 | 0.75 | CDK5 (0.38) | BRD4 | |
| SCHEMBL2317665 | 0.69 | BRD4 (0.31) | BRD4 | |
| SCHEMBL5346142 | 0.69 | BRD4 (0.31) | BRD4 | |
| SCHEMBL2110544 | 0.68 | BRD4 (0.34) | BRD4PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL1892537 | 0.67 | MTNR1A (0.35) | BRD4 | |
| SCHEMBL13616238 | 0.65 | ALDH1A1 (0.38) | ALDH1A1ABL1EGFRSRC | |
| SCHEMBL30372295 | 0.64 | METTL3 (0.34) | ABL1EGFRSRC | |
| SCHEMBL30372731 | 0.64 | LMNA (0.48) | ALDH1A1ABL1EGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2560972-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9682981-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682981-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2012-06-28 | — | — | US | disclosed |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2012-06-28 | — | — | US | disclosed |
| US-8158636-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158636-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-04-17 | — | — | US | disclosed |
| WO-2011133637-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
| WO-2009143018-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | ALDH1A1 3699/4885ACACB 4022/4885BRD4 4621/4885 |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | ALDH1A1 3699/4885ACACB 4022/4885BRD4 4621/4885 |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | ALDH1A1 3699/4885ACACB 4022/4885BRD4 4621/4885 |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, NTRK1, PRKDC | ALDH1A1 3884/4885ACACB 3571/4885BRD4 4349/4885 |
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | ALDH1A1 3834/4885ACACB 3260/4885BRD4 4399/4885 |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | ALDH1A1 3838/4885ACACB 3566/4885BRD4 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.